Yuki Hanai

Nov 20, 2024 | bpspubs.onlinelibrary.wiley.com | Shusuke Uekusa |Misaki Nakashin |Yuki Hanai |Maho Nemoto

What is already known about this subject Lenvatinib mesylate (LEN) therapy for hepatocellular carcinoma is associated with a high incidence of adverse events. Hypertension (HTN) is 1 of the characteristic adverse events of LEN. The risk factors associated with LEN therapy remain unclear. What this study adds Low serum potassium, high serum albumin and low albumin–bilirubin score were identified as risk factors for HTN with LEN.

Aug 27, 2024 | onlinelibrary.wiley.com | Shusuke Uekusa |Yuki Hanai |Maho Nemoto |Misaki Nakashin

1 INTRODUCTION AND BACKGROUND HCC is the most prevalent primary liver cancer worldwide.1, 2 The global incidence of HCC has increased over the last three decades, and this trend is expected to continue until 2030.3 Therefore, the development of safe and effective treatments is important. Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor (TKI).

Aug 16, 2023 | onlinelibrary.wiley.com | Yuki Hanai |Takashi Ueda |Yukihiro Hamada |Kazutaka Oda

1 INTRODUCTION Voriconazole, a broad-spectrum triazole, is an effective agent for the treatment of most clinically significant yeasts and moulds,1-3 and is available in both oral and intravenous formulations.